Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

作者：Hofbauer Christoph J; Whelan Shawn F J; Hirschler Maria; Allacher Peter; Horling Frank M; Lawo John Philip; Oldenburg Johannes; Tiede Andreas; Male Christoph; Windyga Jerzy; Greinacher Andreas; Knoebl Paul N; Schrenk Gerald; Koehn Jadranka; Scheiflinger Friedrich; Reipert Birgit M^*

来源：Blood, 2015, 125(7): 1180-1188.

DOI：10.1182/blood-2014-09-598268

Recently, we reported that distinct immunoglobulin (Ig) isotypes and IgG subclasses of factor VIII (FVIII)-specific antibodies are found in different cohorts of patients with hemophilia A and in healthy individuals. Prompted by these findings, we further investigated the distinguishing properties among the different populations of FVIII-specific antibodies. We hypothesized that the affinity of antibodies would discriminate between the neutralizing and nonneutralizing antibodies found in different study cohorts. To test this idea, we established a competition-based enzyme-linked immunosorbent assay technology to assess the apparent affinities for each isotype and IgG subclass of FVIII-specific antibodies without the need for antibody purification. We present a unique data set of apparent affinities of FVIII-specific antibodies found in healthy individuals, patients with congenital hemophilia A with and without FVIII inhibitors, and patients with acquired hemophilia A. Our data indicate that FVIII-specific antibodies found in patients with FVIII inhibitors have an up to 100-fold higher apparent affinity than that of antibodies found in patients without inhibitors and in healthy individuals. High-affinity FVIII-specific antibodies could be retrospectively detected in longitudinal samples of an individual patient with FVIII inhibitors 543 days before the first positive Bethesda assay. This finding suggests that these antibodies might serve as potential biomarkers for evolving FVIII inhibitor responses.

• 出版日期2015-2-12